Neuren’s Partner Acadia Sees DAYBUE Sales Climbing to US$700m by 2028

An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.

Neuren Pharmaceuticals reported that its partner Acadia Pharmaceuticals is projecting global net sales of Rett syndrome therapy DAYBUE to reach about US$700 million in 2028, underpinned by the US rollout of the new DAYBUE STIX powder formulation, enhanced US commercial infrastructure, and anticipated international expansion including potential European approval. Since the 2023 US launch, more than 2,000 Rett patients have been treated with DAYBUE, 12‑month treatment persistence has improved to 55%, the diagnosed US Rett population has grown to roughly 6,000 patients, and regulatory and clinical milestones are advancing with DAYBUE oral solution now approved in Israel and a Phase 3 trofinetide trial in Japan expected to deliver top-line data between late 2026 and early 2027, collectively strengthening Neuren’s commercial and clinical position in rare neurological disorders.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$21.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing novel drug therapies for serious neurological and neurodevelopmental disorders that emerge in early childhood and have few or no approved treatment options. Its lead products, DAYBUE (trofinetide) and DAYBUE STIX, are approved by the US FDA for the treatment of Rett syndrome and are licensed globally to Acadia Pharmaceuticals, while its second candidate, NNZ-2591, is in Phase 2 development for multiple rare neurodevelopmental syndromes under orphan drug designations in the US and EU.

Average Trading Volume: 337,573

Technical Sentiment Signal: Buy

Current Market Cap: A$2.43B

See more data about NEU stock on TipRanks’ Stock Analysis page.